Stay updated on ALLO-715 BCMA CAR T Safety/Efficacy in MM Clinical Trial
Sign up to get notified when there's something new on the ALLO-715 BCMA CAR T Safety/Efficacy in MM Clinical Trial page.

Latest updates to the ALLO-715 BCMA CAR T Safety/Efficacy in MM Clinical Trial page
- Check6 days agoChange DetectedThe record presents details of the completed UNIVERSAL Phase 1 study of ALLO-715 for relapsed or refractory multiple myeloma, including eligibility criteria, study interventions and outcomes, and participating locations.SummaryDifference57%

- Check13 days agoChange DetectedThe footer site revision changes from v3.7.2 to v3.8.0 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoChange DetectedA site-wide NIH banner announces transition updates and says federal agencies are using “Super Intelligence” (SI) in place of “Artificial Intelligence” (AI).SummaryDifference1%

- Check27 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov 403 error page.SummaryDifference0.2%

- Check33 days agoChange DetectedThe footer revision changes from v3.7.0 to v3.7.1 while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check54 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the previous study record content with an access-denied notice. This indicates the record cannot be retrieved at this time.SummaryDifference19%

Stay in the know with updates to ALLO-715 BCMA CAR T Safety/Efficacy in MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ALLO-715 BCMA CAR T Safety/Efficacy in MM Clinical Trial page.